Shionogi Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHIONOGI INC, and what generic alternatives to SHIONOGI INC drugs are available?
SHIONOGI INC has five approved drugs.
There are four US patents protecting SHIONOGI INC drugs.
There are seventy-two patent family members on SHIONOGI INC drugs in thirty-eight countries and thirty-three supplementary protection certificates in sixteen countries.
Drugs and US Patents for Shionogi Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shionogi Inc | FETROJA | cefiderocol sulfate tosylate | POWDER;INTRAVENOUS | 209445-001 | Nov 14, 2019 | RX | Yes | Yes | 9,949,982 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Shionogi Inc | RYBIX ODT | tramadol hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021693-001 | May 5, 2005 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Shionogi Inc | DORIBAX | doripenem | INJECTABLE;INTRAVENOUS | 022106-002 | Oct 5, 2010 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Shionogi Inc | COGNEX | tacrine hydrochloride | CAPSULE;ORAL | 020070-001 | Sep 9, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Shionogi Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Shionogi Inc | COGNEX | tacrine hydrochloride | CAPSULE;ORAL | 020070-004 | Sep 9, 1993 | 4,631,286 | ⤷ Try a Trial |
Shionogi Inc | COGNEX | tacrine hydrochloride | CAPSULE;ORAL | 020070-002 | Sep 9, 1993 | 4,631,286 | ⤷ Try a Trial |
Shionogi Inc | COGNEX | tacrine hydrochloride | CAPSULE;ORAL | 020070-001 | Sep 9, 1993 | 4,631,286 | ⤷ Try a Trial |
Shionogi Inc | DORIBAX | doripenem | INJECTABLE;INTRAVENOUS | 022106-002 | Oct 5, 2010 | 8,247,402 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SHIONOGI INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 250 mg/vial and 500 mg/vial | ➤ Subscribe | 2011-10-11 |
➤ Subscribe | Lotion | 5% | ➤ Subscribe | 2016-04-11 |
International Patents for Shionogi Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 102203100 | ⤷ Try a Trial |
Israel | 211720 | ⤷ Try a Trial |
Eurasian Patent Organization | 201790522 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2016035846 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shionogi Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1307486 | 12C0041 | France | ⤷ Try a Trial | PRODUCT NAME: CYCLO((4R)-4(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-) : PASIREOTIDE, OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/753/001 20120424 |
2960244 | 132020000000136 | Italy | ⤷ Try a Trial | PRODUCT NAME: CEFIDEROCOL, OPZIONALMENTE NELLA FORMA DI UN SALE FARMACEUTICAMENTE ACCETTABILE O SOLVATO(FETCROJA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1434, 20200424 |
2960244 | 43/2020 | Austria | ⤷ Try a Trial | PRODUCT NAME: CEFIDEROCOL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATS; REGISTRATION NO/DATE: EU/1/20/1434 (MITTEILUNG) 20200424 |
2187879 | SPC/GB17/031 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 1-CHLORO-4-(SS-D-GLUCOPYRANOS-1-YL)-2-(4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL)-BENZENE (I.E. EMPAGLIFLOZIN) IN COMBINATION WITH 1-((4 METHYL-QUINAZOLIN-2-YL)METHYL)-3-METHYL-7-(2-BUTYN-1-YL)-8-(3-(R)-AMINO-PIPERIDIN-1-YL)-XANTHINE (I.E. LINAGLIPTIN) OR A P; REGISTERED: UK PLGB 14598/0191 (GB) 20161115; UK EU/1/16/1146/014(NI) 20161115; UK EU/1/16/1146/015(NI) 20161115; UK EU/1/16/1146/016(NI) 20161115; UK EU/1/16/1146/017(NI) 20161115; UK EU/1/16/1146/018(NI) 20161115; UK EU/1/16/1146/007(NI) 20161115; UK EU/1/16/1146/001(NI) 20161115; UK EU/1/16/1146/013(NI) 20161115; UK EU/1/16/1146/002(NI) 20161115; UK EU/1/16/1146/003(NI) 20161115; UK EU/1/16/1146/004(NI) 20161115; UK... |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.